Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy
Introduction
The diagnostic entity “mild cognitive impairment” refers to cognitive deficits in elderly subjects that exceed age-related cognitive decline but do not fulfil the criteria for dementia. The syndrome is associated with an increased risk for the development of dementia such as Alzheimer's disease (AD), and it is generally assumed that mild cognitive impairment (MCI) reflects preclinical AD in a considerable portion of the affected individuals.
Magnetic resonance spectroscopy (MRS) noninvasively provides information on the concentration of cerebral metabolites in vivo. Changes of these metabolites can be used as markers for neurodegenerative diseases like AD. While it is widely accepted that the MRS-detectable neuronal marker N-acetylasparte (NAA) is decreased in AD (Valenzuela and Sachdev, 2001), the potential of MRS in detecting metabolic changes at the beginning of the disease is still under discussion. Previous cross-sectional studies explicitly investigating NAA changes in MCI compared with cognitively healthy subjects were inconclusive and yielded positive (Ackl et al., 2005, Chantal et al., 2004, Falini et al., 2005, Kantarci et al., 2007) as well as negative findings (Catani et al., 2001, Kantarci et al., 2000, Kantarci et al., 2002).
Diverging results are partly attributable to methodological issues but also reflect the fact that MCI is indeed a heterogeneous condition: While some of the affected subjects develop dementia at follow-up (“converters”), some improve and others remain in a cognitively impaired but stable state (Schönknecht et al., 2005). Accordingly, several recent studies have prospectively addressed the predictive power of MRS-derived metabolic markers with regard to conversion to dementia and revealed some indications that baseline NAA levels were decreased in those subjects who developed dementia at follow-up (Chao et al., 2005, Metastasio et al., 2006, Modrego et al., 2005). Although these findings suggest that NAA can be used as an early (preclinical) marker of AD, little is known about the dynamics of MRS-derived metabolic changes which occur at the onset of clinical manifestations of AD. In particular, it would be relevant to study NAA changes associated with progression of cognitive deficits in MCI subjects converting to dementia. This would not only shed light on the cerebral metabolic changes underlying cognitive decline in MCI but would also support the utility of NAA as an objective surrogate marker of progressive decline in neuronal integrity in early AD.
Accordingly, the purpose of the present study was (1) to longitudinally investigate changes of NAA and other relevant MRS-detectable cerebral metabolites in subjects with MCI compared with cognitively healthy elderly controls, and (2) to analyze these changes with respect to rate of cognitive decline and clinical disease progression.
Section snippets
Subjects and clinical examinations
Fifteen patients with MCI recruited at the Memory Clinic of the Psychiatric Hospital of Frankfurt University and 12 healthy elderly volunteers from the local community were included.
Diagnostic assessment of the MCI patients was performed involving a cooperating multiprofessional team (neurologists, psychiatrists and psychologists). The clinical diagnosis was based on a detailed medical history from both the patient and the spouse or relative; general physical, neurological, and psychiatric
Results
There were no gender differences between the control group and the MCI group. However, patients with MCI were significantly older (68.1 ± 5 vs. 73.1 ± 5.9 years/Table 1). An age-matched comparison can be achieved by comparing the second visit of the controls with the first visit of the patients. The F-values for such a comparison are listed in parentheses in the last column of Table 1, Table 2, Table 3. Already at baseline MCI patients were characterized by a significantly lower MMSE score (29.8 ±
Discussion
In this study we have longitudinally measured MRS-detectable changes of metabolite concentrations in a group of subjects with clinically diagnosed MCI in comparison to a group of healthy age-matched volunteers.
Our main findings include that a longitudinal decline in cognitive function (particularly in memory function) within the MCI group was predicted by a decline in absolute concentrations of the metabolic markers NAA. In the grey matter volume a decline of creatine was observed as well.
References (30)
- et al.
Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease
Neuroscience Letters
(2005) - et al.
Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease
Lancet
(2000) - et al.
Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease
Brain Research
(2004) - et al.
A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment
Neuroimage.
(2005) - et al.
“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician
. Journal of Psychiatric Research.
(1975) - et al.
Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline
American Journal of Geriatric Psychiatry
(2002) - et al.
Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease
Neurobiology of Aging
(2007) - et al.
Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy
Neurobiology of Aging
(2006) - et al.
(1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging
Neuroreport
(2001) - et al.
Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients
Neurology
(2005)
Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease
Brain
Human memory systems
In vivo quantitation of metabolite concentrations in the brain by means of proton MRS
NMR in Biomedicine
Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients
Neurology
Treatment monitoring and response prediction with proton MR spectroscopy in AD
Neurology
Cited by (52)
Magnetic resonance spectroscopy in the hippocampus of adult APP/PS1 mice following chronic vitamin D deficiency
2024, Behavioural Brain ResearchMultivoxel proton magnetic resonance spectroscopy detects thalamic neurochemical metabolic changes in patients with major depressive disorder
2017, Egyptian Journal of Radiology and Nuclear MedicineLow episodic memory performance in cognitively normal elderly subjects is associated with increased posterior cingulate gray matter N-acetylaspartate: a <sup>1</sup>H MRSI study at 7 Tesla
2016, Neurobiology of AgingCitation Excerpt :It has been located in neurons, oligodendrocytes, and myelin, where it is implicated in various biological processes within the central nervous system, including mitochondrial energy production and peptidergic neurotransmission (Clark, 1998; Moffett et al., 2007). Consistent with its elementary role in processes essential for cellular survival, there are several reports of decreased NAA levels in neurodegenerative diseases characterized by progressive loss of brain tissue including clinically manifest AD (Kantarci et al., 2000; Klunk et al., 1992) but also prodromal stages such as MCI (Metastasio et al., 2006; Pilatus et al., 2009; Riese et al., 2015), preclinical familial dementia (Godbolt et al., 2006; Kantarci et al., 2010), or premanifest Huntington's disease (Unschuld et al., 2012). Studies on ischemic and focal brain damage suggest that NAA also reflects reversible changes in neuronal health (Clark, 1998; Demougeot et al., 2004; Gasparovic et al., 2001).
On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey
2016, Artificial Intelligence in MedicineCreatine as a booster for human brain function. How might it work?
2015, Neurochemistry International